Patents Assigned to SAGE THERAPEUTICS, INC.
  • Patent number: 12268697
    Abstract: Compounds are provided according to Formula (I): Formula (I) and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof; wherein R1, R2, R3, R6, R7, R8, and n are as defined herein. Compounds of the present invention are contemplated useful for the prevention and treatment of a variety of conditions.
    Type: Grant
    Filed: March 13, 2024
    Date of Patent: April 8, 2025
    Assignee: Sage Therapeutics, Inc.
    Inventors: Francesco G. Salituro, Albert Jean Robichaud, Gabriel Martinez Botella
  • Patent number: 12264177
    Abstract: Provided herein is a compound of Formula (I) or a pharmaceutically acceptable salt thereof, wherein R19, R5, R3a, R1a, R1b, R2a, R2b, R4a, R4b, R6a, R6b, R7a, R7b, R11a, R11b, R12a, R12b, R18, RD, and q are defined herein. L is selected from the group consisting of: wherein A indicates the point of attachment at C17 and wherein X is selected from the group consisting of —C(O)N(R55a)(R55b), —N(R55a)(R55b), —N(R55b)C(O)(R55a), and R55C wherein R55c is carbon-bound substituted or unsubstituted heteroaryl or substituted or unsubstituted aryl. Also provided herein are pharmaceutical compositions comprising a compound of Formula (I) and methods of using the compounds, e.g., in the treatment of CNS-related disorders.
    Type: Grant
    Filed: March 26, 2024
    Date of Patent: April 1, 2025
    Assignee: Sage Therapeutics, Inc.
    Inventors: Maria Jesus Blanco-Pillado, Francesco G. Salituro, Marshall Lee Morningstar
  • Patent number: 12252509
    Abstract: Provided herein is a compound of Formula (I) or a pharmaceutically acceptable salt thereof, wherein R19, R5, R3a, R1a, R1b, R2a, R2b, R4a, R4b, R6a, R6b, R7a, R7b, R11a, R11b, R12a, R12b, R18, RD, and q are defined herein. L is selected from the group consisting of: wherein A indicates the point of attachment at C17 and wherein X is selected from the group consisting of —C(O)N(R55a)(R55b), —N(R55a)(R55b), —N(R55b)C(O)(R55a), and R55C wherein R55c is carbon-bound substituted or unsubstituted heteroaryl or substituted or unsubstituted aryl. Also provided herein are pharmaceutical compositions comprising a compound of Formula (I) and methods of using the compounds, e.g., in the treatment of CNS-related disorders.
    Type: Grant
    Filed: March 26, 2024
    Date of Patent: March 18, 2025
    Assignee: Sage Therapeutics, Inc.
    Inventors: Maria Jesus Blanco-Pillado, Francesco G. Salituro, Marshall Lee Morningstar
  • Patent number: 12201640
    Abstract: Provided herein are 19-nor C3,3-disubstituted C21-pyrazolyl steroids of Formula (I): and pharmaceutically acceptable salts thereof; wherein , R1, R2, R3a, R3b, R4a, R4b, R5, R6, and R7 are as defined herein. Such compounds are contemplated useful for the prevention and treatment of a variety of CNS-related conditions, for example, treatment of sleep disorders, mood disorders, schizophrenia spectrum disorders, convulsive disorders, disorders of memory and/or cognition, movement disorders, personality disorders, autism spectrum disorders, pain, traumatic brain injury, vascular diseases, substance abuse disorders and/or withdrawal syndromes, and tinnitus.
    Type: Grant
    Filed: December 23, 2021
    Date of Patent: January 21, 2025
    Assignee: Sage Therapeutics, Inc.
    Inventors: Gabriel Martinez Botella, Boyd L. Harrison, Albert Jean Robichaud, Francesco G. Salituro, Richard Thomas Beresis
  • Patent number: 12180247
    Abstract: Compounds are provided according to Formula (A): and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof; wherein R1, R2, R3, R4, R5, R6, and RG are as defined herein. Compounds of the present invention are contemplated useful for the prevention and treatment of a variety of conditions.
    Type: Grant
    Filed: February 6, 2023
    Date of Patent: December 31, 2024
    Assignee: Sage Therapeutics, Inc.
    Inventors: Francesco G. Salituro, Albert Jean Robichaud, Gabriel Martinez Botella, Boyd L. Harrison, Andrew Griffin
  • Patent number: 12180248
    Abstract: Described herein are neuroactive steroids of the Formula (I): or a pharmaceutically acceptable salt thereof; wherein, R1, R2a, R2b, R3 and A are as defined herein. Such compounds are envisioned, in certain embodiments, to behave as GABA modulators. The present invention also provides pharmaceutical compositions comprising a compound of the present invention and methods of use and treatment, e.g., such for inducing sedation and/or anesthesia.
    Type: Grant
    Filed: February 16, 2023
    Date of Patent: December 31, 2024
    Assignee: Sage Therapeutics, Inc.
    Inventors: Gabriel Martinez Botella, Francesco G. Salituro, Albert Jean Robichaud, Boyd L. Harrison
  • Patent number: 12129276
    Abstract: Compounds are provided according to Formula (I) and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, wherein X, Y, R1, R2a, R2b, R4a, R4b, R5a, R5b, R6a, R6b, R7, and R8 are as defined herein. Compounds of the present invention are contemplated useful for the prevention and treatment of a variety of conditions.
    Type: Grant
    Filed: March 2, 2023
    Date of Patent: October 29, 2024
    Assignee: SAGE THERAPEUTICS, INC.
    Inventors: Boyd L. Harrison, Gabriel Martinez Botella, Albert Jean Robichaud, Francesco G. Salituro
  • Patent number: 12129275
    Abstract: Compounds are provided according to Formula (I) and pharmaceutically acceptable salts thereof, wherein Z is a group of the formula (i), (ii), (iii), (iv), or (v), and wherein L1, L2, L3, X1, X2, Y, Rz4, Rz5, Rz6, n, R1, R2, R3a, R3b, R4a, R4b, R6a, R6b, R7a, R7b, R11a, R11b, R14, R17, R19, R20, R23a, R23b, and R24 are as defined herein, and pharmaceutical compositions thereof. Compounds of the present invention are contemplated useful for the prevention and treatment of a variety of CNS-related conditions in mammals.
    Type: Grant
    Filed: March 29, 2022
    Date of Patent: October 29, 2024
    Assignee: SAGE THERAPEUTICS, INC.
    Inventors: Ravindra B. Upasani, Boyd L. Harrison, Benny C. Askew, Jean-Cosme Dodart, Francesco G. Salituro, Albert Jean Robichaud
  • Patent number: 12122803
    Abstract: This invention relates to crystalline forms of anhydrous Compound (1) and pharmaceutical compositions thereof. Also disclosed herein are methods of making crystalline solid forms of Compound (1), and methods of using the crystalline forms of Compound (1) and pharmaceutical compositions thereof for modulating GABA activity (e.g., positive allosteric modulation of GABA activity) and treating CNS-related disorders.
    Type: Grant
    Filed: March 7, 2024
    Date of Patent: October 22, 2024
    Assignee: Sage Therapeutics, Inc.
    Inventors: Shanming Kuang, Tianrui Li
  • Patent number: 12083131
    Abstract: Described herein are methods of treating tremor, e.g., essential tremor, depression, e.g., postpostum depression; and anxiety disorder, the method comprising administering to a human subject suffering from tremor, e.g., essential tremor; depression, e.g., postpostum depression, an anxiety disorder with a neuroactive steroid or a composition comprising a neuroactive steroid (e.g., pregnanolone, allopregnanolone, alphadalone, ganaxolone, or alphaxolone).
    Type: Grant
    Filed: February 10, 2020
    Date of Patent: September 10, 2024
    Assignee: Sage Therapeutics, Inc.
    Inventors: Stephen Jay Kanes, Helen Colquhoun
  • Patent number: 12071453
    Abstract: Described herein are neuroactive steroids of the Formula (I): or a pharmaceutically acceptable salt thereof; wherein -------, R1, R2, R3, A and L are as defined herein. Such compounds are envisioned, in certain embodiments, to behave as GABA modulators. The present invention also provides pharmaceutical compositions comprising a compound of the present invention and methods of use and treatment, e.g., such for inducing sedation and/or anesthesia.
    Type: Grant
    Filed: September 26, 2022
    Date of Patent: August 27, 2024
    Assignee: Sage Therapeutics, Inc.
    Inventors: Gabriel Martinez Botella, Boyd L. Harrison, Albert Jean Robichaud, Francesco G. Salituro, Robert Jason Herr, Robert Borbo Kargbo
  • Patent number: 12065463
    Abstract: Described herein are neuroactive steroids of the Formula (I): or a pharmaceutically acceptable salt thereof, wherein , A, R1, R2, R3a, R4a, R4b, R5, R7a, and R7b are as defined herein. Such compounds are envisioned, in certain embodiments, to behave as GABA modulators. The present invention also provides pharmaceutical compositions comprising a compound of the present invention and methods of use and treatment, e.g., such for inducing sedation and/or anesthesia.
    Type: Grant
    Filed: October 24, 2022
    Date of Patent: August 20, 2024
    Assignee: Sage Therapeutics, Inc.
    Inventors: Gabriel Martinez Botella, Francesco G. Salituro, Albert Jean Robichaud, Boyd L. Harrison
  • Patent number: 12060386
    Abstract: Provided herein is a compound of Formula (I) or a pharmaceutically acceptable salt thereof, wherein R3a, R5, R6a, R6b, R17, R21a, R21b, Rm, Rn, R16a, R16b, R7a, R7b, R12a, R12b, R11a, R11b, R2a, R2b, R19, R4a, and R4b are defined herein. Also provided herein are pharmaceutical compositions comprising a compound of Formula (I) and methods of using the compounds, e.g., in the treatment of CNS-related disorders.
    Type: Grant
    Filed: April 24, 2023
    Date of Patent: August 13, 2024
    Assignee: Sage Therapeutics, Inc.
    Inventors: Francesco G. Salituro, Albert Jean Robichaud
  • Patent number: 12048706
    Abstract: Described herein are methods of treating epilepsy or status epilepticus, e.g., convulsive status epilepticus, e.g., early status epilepticus, established status epilepticus, refractory status epilepticus, super-refractory status epilepticus, e.g., super-refractory generalized status epilepticus; non-convulsive status epilepticus, e.g., generalized status epilepticus, complex partial status epilepticus; generalized periodic epileptiform discharges; periodic lateralized epileptiform discharges; a seizure, e.g., acute repetitive seizures, cluster seizures, the method comprising administering to the subject a neuroactive steroid.
    Type: Grant
    Filed: February 3, 2022
    Date of Patent: July 30, 2024
    Assignee: Sage Therapeutics, Inc.
    Inventors: Kiran Reddy, Stephen J. Kanes
  • Patent number: 11999765
    Abstract: Provided herein is a compound of Formula (I) or a pharmaceutically acceptable salt thereof, wherein R19, R5, R3a, R1a, R1b, R2a, R2b, R4a, R4b, R6a, R6b, R7a, R7b, R11a, R11b, R12a, R12b, R18, RD, and q are defined herein. L is selected from the group consisting of: wherein A indicates the point of attachment at C17 and wherein X is selected from the group consisting of —C(O)N(R55a)(R55b), —N(R55a)(R55b), —N(R55b)C(O)(R55a), and R55C wherein R55c is carbon-bound substituted or unsubstituted heteroaryl or substituted or unsubstituted aryl. Also provided herein are pharmaceutical compositions comprising a compound of Formula (I) and methods of using the compounds, e.g., in the treatment of CNS-related disorders.
    Type: Grant
    Filed: June 13, 2023
    Date of Patent: June 4, 2024
    Assignee: Sage Therapeutics, Inc.
    Inventors: Maria Jesus Blanco-Pillado, Francesco G. Salituro, Marshall Lee Morningstar
  • Patent number: 11993628
    Abstract: Described herein are neuroactive steroids of Formula (I), Formula (V), or Formula (IX) or a pharmaceutically acceptable salt thereof; wherein each instance of R2, R3, R4, R5, R6, R7, R11a, R11b, R12, R16, R17, R19, and are as defined herein. Such compounds are envisioned, in certain embodiments, to behave as GABA modulators. Also provided are pharmaceutical compositions comprising a compound described herein and methods of use and treatment, e.g., such as for inducing sedation and/or anesthesia.
    Type: Grant
    Filed: April 28, 2021
    Date of Patent: May 28, 2024
    Assignee: Sage Therapeutics, Inc.
    Inventors: Albert Jean Robichaud, Gabriel Martinez Botella, Boyd L. Harrison, Francesco G. Salituro, Andrew Griffin, Maria Jesus Blanco-Pillado
  • Patent number: 11970514
    Abstract: Provided herein is a compound of Formula (I) or a pharmaceutically acceptable salt thereof, wherein R19, R5, R3a, R1a, R1b, R2a, R2b, R4a, R4b, R6a, R6b, R7a, R7b, R11a, R11b, R12a, R12b, R18, RD, and q are defined herein. L is selected from the group consisting of: wherein A indicates the point of attachment at C17 and wherein X is selected from the group consisting of —C(0)N(R55a)(R55b), —N(R55a)(R55b), —N(R55b)C(O)(R55a), and R55C wherein R55c is carbon-bound substituted or unsubstituted heteroaryl or substituted or unsubstituted aryl. Also provided herein are pharmaceutical compositions comprising a compound of Formula (I) and methods of using the compounds, e.g., in the treatment of CNS-related disorders.
    Type: Grant
    Filed: June 13, 2023
    Date of Patent: April 30, 2024
    Assignee: Sage Therapeutics, Inc.
    Inventors: Maria Jesus Blanco-Pillado, Francesco G. Salituro, Marshall Lee Morningstar
  • Patent number: 11952397
    Abstract: This invention relates to crystalline forms of anhydrous Compound (1) and pharmaceutical compositions thereof. Also disclosed herein are methods of making crystalline solid forms of Compound (1), and methods of using the crystalline forms of Compound (1) and pharmaceutical compositions thereof for modulating GABA activity (e.g., positive allosteric modulation of GABA activity) and treating CNS-related disorders.
    Type: Grant
    Filed: August 2, 2023
    Date of Patent: April 9, 2024
    Assignee: Sage Therapeutics, Inc.
    Inventors: Shanming Kuang, Tianrui Li
  • Patent number: 11945836
    Abstract: Described herein are neuroactive steroids of the Formula (II): or a pharmaceutically acceptable salt thereof; wherein A, R1, R2a, R2b, R3a, R3b, R4a, R4b, R5, R6 and are as defined herein. Such compounds are envisioned, in certain embodiments, to behave as GABA modulators. The present invention also provides pharmaceutical compositions comprising a compound of the present invention and methods of use and treatment, e.g., such for inducing sedation and/or anesthesia.
    Type: Grant
    Filed: October 4, 2022
    Date of Patent: April 2, 2024
    Assignee: Sage Therapeutics, Inc.
    Inventors: Gabriel Martinez Botella, Boyd L. Harrison, Albert Jean Robichaud, Francesco G. Salituro, Richard Thomas Beresis
  • Patent number: 11926646
    Abstract: Compounds are provided according to Formula (A): and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof; wherein R1A, R1B, n, R2A, R2B, R3, and R4 are as defined herein. Compounds of the present invention are contemplated useful for the prevention and treatment of a variety of conditions.
    Type: Grant
    Filed: September 15, 2021
    Date of Patent: March 12, 2024
    Assignee: Sage Therapeutics, Inc.
    Inventors: Francesco G. Salituro, Albert Jean Robichaud, Gabriel Martinez Botella, Andrew Griffin, Boyd L. Harrison, Daniel La